Dublin, Sept. 29, 2022 (GLOBE NEWSWIRE) — The “Global Latent Tuberculosis Infection (LTBI) Testing Market: Analysis by Type (LTBI Tuberculin Skin Test and LTBI Interferon Gamma Release Test (IGRA) ), by region size and The “Trends with impact of COVID-19 and forecast to 2027” report has been added to from ResearchAndMarkets.com offer.
Global Latent Tuberculosis Infection (LTI) Testing Market in 2021 was valued at USD 1.75 Billion and is projected to reach USD 2.47 Billion by 2027, growing at a CAGR of 5.95 % in 2022-2027
Latent tuberculosis tests diagnose latent tuberculosis which is the type of tuberculosis infection where the bacterium remains inactive i.e. the bacterium is present in a dormant state inside the body. This infection can only be manifested by the tuberculin skin test (TST). Despite this, there is a lingering risk that latent infection could progress to active tuberculosis. The risk is increased by other illnesses such as HIV, drug addiction or drugs that weaken the immune system.
Due to the aging of the population, the upsurge in the consumption of cigarettes, and the growth in pharmaceutical research and development, the market is expected to propel in the coming years. The global LTBI testing market volume reached 83.84 million in 2021.
Aging population is one of the most important factors impacting the global Latent Tuberculosis Infection (LTBI) Testing market. Since the elderly are very likely to have latent tuberculosis infection as an underlying disease, age-related decline in immune function, increased frequency of adverse drug reactions, and institutionalization may complicate the comprehensive clinical approach to tuberculosis in elderly patients.
As the aging population continues to grow, the risk of prevalence of latent tuberculosis among them also tends to increase, which expands the scope of the growth of the global latent tuberculosis infection testing market in the years to come.
Additionally, the market has witnessed growth over the past few years, driven by factors such as rapid urbanization, rising HIV prevalence, accelerating funding for TB, accelerating construction activities, increase in consumer spending, escalating government initiatives and many other factors.
However, the market faced some challenges including multi-drug resistant tuberculosis (MDR-TB), stringent government regulations, etc.
The market is expected to grow at a rapid rate over the forecast period, owing to various recent trends such as rising healthcare spending in emerging markets, online probe testing (LPA), nucleic acid amplification (NAAT), expanding advanced and hybrid techniques. , etc.
The expansion of advanced and hybrid techniques has greatly affected the clinical use of these, leading to an increase in the application of advanced testing techniques in the diagnosis of latent tuberculosis.
Hence, the expansion of advanced and hybrid techniques is expected to create growth opportunities for the global LTBI testing market.
Market Segmentation Analysis:
In 2021, the LTBI tuberculin skin test segment held a significant share of over 60% in the market. On the other hand, interferon gamma release assay (IGRA) segment is expected to grow at the highest CAGR in the coming years owing to the growth in pharmaceutical research and development, increasing prevalence of HIV and of growing urbanization.
North America held the largest share of more than 40% of the market, owing to high R&D spending and increasing cigarette consumption.
In North America, the United States is expected to be the fastest growing region during the forecast period. The United States continues to have one of the lowest TB case rates in the world. However, according to the Centers for Disease Control and Prevention (CDC), a significant percentage of people still suffer from TB and progress towards eliminating TB is relatively slow in the country.
Whereas, in the Europe region, Germany held nearly 31% market share due to rising healthcare spending, growing urbanization, and advanced and hybrid technologies.
COVID-19 impact analysis and way forward:
The provision of TB health services (TB diagnosis, care and prevention services) and access to these services have been severely disrupted by COVID-19. TB service providers in many high TB burden settings have faced challenges in delivering services, due to lack of appropriate equipment and capacity, movement restrictions (affecting health workers, commodities and inventory) and the reallocation of resources.
The COVID-19 pandemic reversed the significant progress that had been made in the global fight against TB, causing many TB reduction targets to be missed. Recently, few studies have proven that COVID-19 may have been considered in the case of ITL reactivation. This is consistent with the knowledge that LTBI is reactivated as part of immunosuppression.
Given its high worldwide prevalence and relatively high lifetime risk of reactivation, estimated at 5% to 10%, screening for LTBI should be considered in certain populations, especially in the context of the COVID pandemic. -19.
The global LTBI testing market is moderately fragmented, with a large number of small and medium-sized manufacturers accounting for a significant share of revenue.
Some of the strategies among the major market players in the LTBI Market are mergers, acquisitions, and collaborations. For example, in 2022, Sanofi SA announced a collaboration with Innovent Biologics to bring innovative medicines to patients in China with difficult-to-treat cancers.
Whereas Becton, Dickinson & Company announced a collaboration agreement with Labcorp, a global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry (CDx)-based companion diagnostics for connecting patients to life-changing treatments for cancer and other diseases.
Major Players of Global LTBI Testing Market are:
- Roche Holding SA
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Sanofi SA
- Endo International plc
- Becton, Dickinson and company
- PerkinElmer, Inc.
- Bio-rad Laboratories, Inc.
- BioMérieux SA
- Qiagen AG
- Cyrus Poonawalla Group (Serum Institute of India Pvt. Ltd.)
- Bruker Corporation
Main topics covered:
2.1 Screening for latent tuberculosis infection: an overview
2.2 Segmentation of LTBI tests: an overview
3. Global Market Analysis
3.1 Global LTBI Testing Market: An Analysis
3.2 Global LTBI Testing Market: Type Analysis
3.3 Global LTBI Testing Market Volume: An Analysis
3.4 Global LTBI Testing Market Volume: Type Analysis
4. Regional Market Analysis
4.1 North America LTBI Testing Market: An Analysis
4.2 Europe LTBI Testing Market: An Analysis
4.3 Asia-Pacific LTBI Testing Market: An Analysis
4.4 Middle East & Africa LTBI Testing Market: An Analysis
4.5 Latin America LTBI Testing Market: An Analysis
5. Impact of COVID-19
5.1 Impact of COVID-19
5.1.1 Impact of COVID-19 on the LTBI Testing Market
5.1.2 Impact of COVID-19 on the poverty rate
5.1.3 Impact of COVID-19 on the geriatric population and the treatment of latent tuberculosis
5.1.4 Post-COVID-19 Impact on the Global ITL Market
6. Market dynamics
6.1 Drivers of growth
6.1.1 Population aging
6.1.2 Rise in cigarette consumption
6.1.3 Increase in HIV prevalence
6.1.4 Urbanization leading to monitoring and selection procedures
6.1.5 Growth in Pharmaceutical Research and Development
6.2.1 Multidrug-resistant tuberculosis (MDR-TB)
6.2.2 Strict government regulations
6.2.3 Lack of laboratory facilities
6.3 Market trends
6.3.1 Rising Healthcare Spending in Emerging Markets
6.3.2 Accelerating funding for TB
6.3.3 Online Probe Tests (LPA)
6.3.4 Nucleic Acid Amplification Assays (NAATs)
6.3.5 Expansion of advanced and hybrid technique
6.3.6 Escalation of government initiatives
7. Competitive landscape
7.1 Global LTBI Testing Market Players by Market Capitalization
7.2 Global LTBI Testing Market Players by R&D Comparison
8. Company Profiles
8.1 Overview of activities
8.2 Operating area
8.3 Business strategy
For more information about this report visit https://www.researchandmarkets.com/r/4ievc7